PCRX Q4 2023 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$181M+5.4% YoY

Gross Profit

$134M73.7% margin

Operating Income

$33M18.3% margin

Net Income

$25M13.7% margin

EPS (Diluted)

$0.48

QoQ Revenue Growth

+10.6%

Cash Flow

Operating Cash Flow

$48M

Free Cash Flow

$46M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$704M

Stockholders' Equity

$870M

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181M	$172M	+5.4%
Gross Profit	$134M	$110M	+21.4%
Operating Income	$33M	-$10M	+435.3%
Net Income	$25M	-$10M	+346.2%

Revenue Segments

Product

$180M86%

ZILRETTA

$29M14%

Bupivacaine Liposome Injectable Suspension

$1M1%